BrainVectis
About BrainVectis
BrainVectis' aim is to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Based on work carried out by Dr. Nathalie Cartier-Lacave and her team at the UMR1169 unit (INSERM/CEA) and by her collaborators (INSERM/UMR-S 1130, UMR 8246-CNRS), BrainVectis is currently focusing on Huntington's disease and Alzheimer's disease, two serious and irreversible diseases for which as yet no effective treatment exists. BrainVectis is based in Fontenay aux Roses and has five employees. The company raised €1 million ($1.1m) in September 2016 in a series A round of financing.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder and CEO: Jerome Becquart, PhD
Founder and CSO: Nathalie Cartier-Lacave, MD
2 articles about BrainVectis
-
BrainVectis will begin assessing a gene therapy for Huntington’s disease in France after receiving clearance from health authorities there to conduct a Phase I/II study.
-
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
4/22/2020
Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company, announced that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders.